Form 4: Sarepta Therapeutics EVP Cristin Rothfuss Reports Stock Sale for Tax Obligations

Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, reports the sale of shares to cover tax obligations related to vesting restricted stock units.

Summary

• On March 3, 2025, Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, sold 391 shares of common stock to satisfy tax withholding obligations related to the vesting of restricted stock units.
• The sale price was $103.77 per share.
• Following the transaction, Rothfuss beneficially owns 13,621 shares of Sarepta Therapeutics, Inc.
• This amount includes 195 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2025.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a routine transaction. It doesn't indicate positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like executives or directors, trade their company's stock. These filings provide transparency into the transactions of those with access to non-public information.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The sale of shares to cover tax obligations related to vesting equity is a common occurrence among executives.
• There are no specific industry benchmarks for this type of transaction, as it is based on individual circumstances and compensation structures.

Stakeholder Impact

• The transaction has a minimal impact on shareholders, as it is a small percentage of the total outstanding shares.
• The sale does not directly affect employees, customers, suppliers, or creditors.

Key Dates